FINWIRES · TerminalLIVE
FINWIRES

e.l.f. Beauty Faces 'Tricky Quarter' Ahead of Earnings, UBS Says

By

e.l.f. Beauty (ELF) could face a "tricky quarter" ahead of its fiscal Q4 results next week, with investors likely to focus more on the company's outlook than quarterly performance, UBS said in a note emailed Wednesday.

The brokerage said that "much of the focus will center on initial FY27 guidance rather than the quarter itself," adding that investors are concerned if the company can perform and "provide an outlook that appears more than achievable without causing concern on the top line trajectory given tougher comps on the horizon."

UBS said quarterly results are likely to be broadly in line with Wall Street expectations, while strong performance from rhode could provide some support to revenue growth.

UBS expects fiscal 2027 guidance to be conservative, citing "challenging consumer backdrop."

UBS maintained a neutral rating with a $70 price target.

Price: $53.77, Change: $-1.89, Percent Change: -3.40%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP